BeiGene Ltd. (688235)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BeiGene Ltd. (688235)
Company Performance

Current Price

as of Oct 16, 2024

$24.21

P/E Ratio

N/A

Market Cap

$24.6B

Description

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Metrics

Overview

  • HQGeorge Town, GT
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • Ticker688235
  • Price$24.205382-1.59%

Trading Information

  • Market Cap$24.60B
  • Float8.33%
  • Average Daily Volume (1m)2,892,396
  • Average Daily Volume (3m)2,137,442
  • EPS-$2.79

Company

  • Revenue$22.38B
  • Rev Growth (1yr)61.04%
  • Net Income-$872.01M
  • Gross Margin82.58%
  • EBITDA Margin-8.85%
  • EBITDA-$595.54M
  • EV$146.58B
  • EV/Revenue6.55
  • P/EN/A
  • P/S10.48
  • P/B9.71
Documents
Factset Street Account
StreetAccount Metrics Recap - BeiGene Q3 Earnings ($189.37, 0.00) (2023-11-09T21:10:21Z)
StreetAccount Consensus Metrics Preview - BeiGene Q3 Earnings (HK$120.00, 0.00) (2023-11-08T23:52:18Z)
NMPA accepts submission of BeiGene's sBLA for combining tislelizumab with chemotherapy for ES-SCLC (09:43 HKT/21:43 ET) (HK$101.50, -3.00) (2023-10-18T07:43:09Z)
NICE recommends BeiGene's Brukinsa to treat CLL in adults ($184.93, 0.00) (2023-11-22T06:25:29Z)
FDA releases briefing documents ahead of Thursday Adcom ($266.31, 0.00) (2023-10-03T13:27:48Z)
FDA grants orphan drug designation to BeiGene for Sonrotoclax to treat multiple myeloma ($184.74, -3.14) (2023-11-21T14:53:29Z)
FDA grants orphan drug designation to BeiGene for sonrotoclax to treat AML ($183.02, +0.56) (2023-12-19T14:56:59Z)
BeiGene reports Q3 EPS $0.15 vs FactSet ($3.38) [7 est, ($4.72)-(2.69)] ($189.00, 0.00) (2023-11-09T21:07:44Z)
BeiGene receives positive CHMP opinion for BRUKINSA (zanubrutinib) in relapsed or refractory follicular lymphoma ($175.15, -1.08) (2023-10-13T15:53:41Z)
BeiGene receives European Commission approval for BRUKINSA (zanubrutinib) for the treatment of relapsed or refractory follicular lymphoma ($189.17, 0.00) (2023-11-17T11:06:02Z)
BeiGene announces late-breaking data at ESMO showing tislelizumab plus chemotherapy significantly improved overall survival at final analysis in first-line advanced gastric or gastroesophageal junction adenocarcinoma ($171.01, 0.00) (2023-10-17T20:05:31Z)
BeiGene and Ensem Therapeutics announce partnership to advance differentiated CDK2 inhibitor ($187.88, 0.00) (2023-11-21T11:03:12Z)
Amgen issues statement on previously reported panel vote ($265.08, 0.00) (2023-10-05T21:23:12Z)
Wikipedia
BeiGene
Factset
Factset Business Description